Voloridge Investment Management LLC Has $1.11 Million Stock Holdings in Bruker Co. (NASDAQ:BRKR)

Voloridge Investment Management LLC boosted its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 179.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,906 shares of the medical research company's stock after purchasing an additional 12,145 shares during the quarter. Voloridge Investment Management LLC's holdings in Bruker were worth $1,108,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Two Sigma Advisers LP increased its stake in Bruker by 406.1% during the fourth quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company's stock worth $8,248,000 after acquiring an additional 112,900 shares during the last quarter. Two Sigma Investments LP lifted its holdings in Bruker by 129.5% during the 4th quarter. Two Sigma Investments LP now owns 516,232 shares of the medical research company's stock worth $30,262,000 after buying an additional 291,313 shares during the last quarter. Toronto Dominion Bank acquired a new stake in shares of Bruker during the fourth quarter worth about $2,931,000. Steadfast Capital Management LP acquired a new stake in shares of Bruker during the fourth quarter worth about $63,997,000. Finally, Scientech Research LLC acquired a new stake in shares of Bruker during the fourth quarter worth about $1,179,000. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Price Performance

Bruker stock traded down $0.63 during trading hours on Friday, hitting $36.63. 1,470,266 shares of the stock were exchanged, compared to its average volume of 1,614,427. Bruker Co. has a 12 month low of $34.10 and a 12 month high of $72.94. The stock has a market capitalization of $5.55 billion, a P/E ratio of 48.20, a P/E/G ratio of 2.16 and a beta of 1.23. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The business's 50-day moving average is $38.62 and its two-hundred day moving average is $49.01.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. The firm had revenue of $801.40 million for the quarter, compared to analysts' expectations of $763.83 million. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The business's revenue for the quarter was up 11.0% on a year-over-year basis. During the same period last year, the firm earned $0.53 earnings per share. Equities research analysts expect that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Monday, June 16th will be paid a dividend of $0.05 per share. The ex-dividend date is Monday, June 16th. This represents a $0.20 annualized dividend and a dividend yield of 0.55%. Bruker's dividend payout ratio is presently 38.46%.

Analyst Ratings Changes

Several equities analysts recently issued reports on BRKR shares. Citigroup cut Bruker from a "strong-buy" rating to a "hold" rating and dropped their price target for the company from $50.00 to $40.00 in a research report on Thursday, May 22nd. Barclays reduced their target price on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. The Goldman Sachs Group decreased their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Wells Fargo & Company decreased their price objective on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Finally, Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Bruker has an average rating of "Hold" and a consensus target price of $59.10.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.